Galectin 10-Q: Going Concern Warning, Cash Funds Operations Only Through June 2027
GALT sits 53% above its 52-week low of $2.025.
Summary
Galectin's Q3 2026 10-Q flags substantial doubt about going concern, with cash and the chairman's line of credit funding operations only through June 2027. The July conversion of $105.8M of chairman debt into 34.4M shares sharply reduced liabilities but left the company dependent on new financing.
Key Events · Earnings and Guidance · GALT
-
Going Concern Warning Disclosed
Management states substantial doubt about the ability to continue as a going concern for 12 months from issuance, with $11.7M of unrestricted cash and a $10M undrawn chairman line of credit funding planned operations only through June 2027.
-
Chairman Debt Conversion Cuts Liabilities
On July 31, 2026, Richard Uihlein converted $91.0M of principal plus $14.8M of accrued interest into 34,376,167 shares at a blended ~$3.07 per share, dropping total liabilities to $46.4M from $145.7M at December 31, 2025.
-
Loss Narrows as R&D Falls
Nine-month net loss was $17.7M versus $25.3M a year earlier, as R&D fell to $5.9M from $12.4M following completion of the NAVIGATE trial; Q3 net loss was $3.5M.
-
Material Weakness Reaffirmed
Disclosure controls were concluded not effective as of September 30, 2026 due to a previously disclosed material weakness over the valuation of derivative liabilities tied to contingent interest on convertible notes.
Analysis · GALT · Life Sciences
The headline is a first-time substantial-doubt going-concern statement: $11.7M of cash plus a $10M undrawn chairman line of credit funds planned operations only through June 2027, and the company has no revenue and no funded trial beyond the Phase 3 protocol filed in Q3. The offset is the July 31 conversion of $105.8M of chairman debt into 34,376,167 shares, which wiped out nearly all liabilities (total liabilities fell to $46.4M from $145.7M), cut interest expense, and left a $35.2M stockholders' deficit instead of $127.9M. Existing holders should weigh that cleanup against the fact that Mr. Uihlein now controls roughly 44.3% of voting power and the company still must raise cash to start Phase 3.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GALT was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $307.6M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.